A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates-Reference-Cited by-同舟云学术

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

Published:2015-05-27 Issue:289 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chichili Gurunadh R.¹,Huang Ling¹,Li Hua¹,Burke Steve¹,He Leilei¹,Tang Qin¹,Jin Linda¹,Gorlatov Sergey¹,Ciccarone Valentina¹,Chen Francine¹,Koenig Scott¹,Shannon Michele¹,Alderson Ralph¹,Moore Paul A.¹,Johnson Syd¹,Bonvini Ezio¹

Affiliation:

1. MacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.

Abstract

MGD006, a CD3xCD123 bispecific DART molecule intended for AML treatment, shows anticancer activity in mouse model and favorable pharmacodynamic and safety profile in nonhuman primates.

Funder

MacroGenics

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference38 articles.

1. Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies;Muñoz L.;Haematologica,2001

2. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

3. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

4. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

5. Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DARPin-fused T cell engager for adenovirus-mediated cancer therapy;Molecular Therapy: Oncology;2024-09

2. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

3. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells;Journal of Hematology & Oncology;2024-08-14

4. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile;Blood Advances;2024-04-26

5. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells;Cancer Immunology Research;2024-04-25